期刊文献+

中段尿培养病原菌分布与耐药性变迁 被引量:9

Distribution and antimicrobial resistance change of pathogens cultured from midstream urine
原文传递
导出
摘要 目的监测和分析扬州地区2009-2011年中段尿培养病原菌分布和耐药性变迁,为临床合理选用抗菌药物提供依据。方法采用法国生物梅里埃公司的VITEK-32全自动微生物仪,进行细菌鉴定和药物敏感试验,应用WHONET 5.3软件分析分离的病原菌的分布及药敏情况。结果 2009-2011年的尿路感染中大肠埃希菌仍位于首位(35.19%~42.19%);肺炎克雷伯菌、粪肠球和屎肠球菌的感染率有上升趋势,分别从2009年5.66%、3.68%、3.77%上升至2011年7.31%、4.78%、5.43%;奇异变形菌检出率有下降趋势,从2009年的5.92%降至2011年的3.87%;大肠埃希菌对头孢哌酮/舒巴坦、亚胺培南、美罗培南、哌拉西林/他唑巴坦、头孢西丁和阿米卡星的敏感率均>90.00%;喹诺酮类药物的敏感率稳定在约45.00%;头孢类药物的耐药率均有上升趋势。结论定期监测和分析当地患者尿路感染病原菌种类及其耐药性变迁,对指导临床合理使用抗菌药物具有重要意义。 OBJECTIVE To detect the distribution of bacteria cultured from the midstream urine and analyze their drug resistance from 2009 to 2011 in Yangzhou area so as to provide the latest evidence for the clinical rational use of antibiotics.METHODS VITEK system was applied to identify bacteria and drug susceptibility testing.WHONET 5.3 software was used to analyze the distribution and drug sensitivity of pathogenic bacteria cultured from the midstream urine.RESULTS From 2009 to 2011,Escherichia coli causing urinary tract infections still ranked the first place(35.19%-42.19%),and incidence rates of Klebsiella pneumoniae infections,Enterococcus faecalis infections and Enterococcus faecium infections kept an upward tendency,respectively increasing from 5.66%,3.68%,and 3.77% in 2009 to 7.31%,4.78%,and 5.43% in 2011,however,the incidence rate of Proteus mirabilis decreased from 5.92% in 2009 to 3.87% in 2011.The drug susceptibility rates of E.coli to cefoperazone/sulbactam,imipenem,meropenem,piperacillin/tazobactam,cefoxitin and amikacin were higher than 90.00%,and the susceptibility rate to quinolones was stably at around 45.00%,the resistance rate to cephalosporins was increased.CONCLUSION It is of great significance in the guidance of reasonable use of antibiotics to regularly monitor and analyze the species of pathogens causing urinary tract infections and the change of their drug resistance.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2013年第8期1958-1960,共3页 Chinese Journal of Nosocomiology
基金 江苏省苏北人民医院课题基金(yzucms 201130)
关键词 中段尿 病原菌 耐药性 Midstream urine Pathogen Drug resistance
  • 相关文献

参考文献4

  • 1李贵玲,韩崇旭,曹艳,顾兵,梅亚宁,刘根焰,潘世扬,童明庆.南京地区2006-2009年中段尿培养病原菌分布及耐药性变迁[J].中华医院感染学杂志,2011,21(3):592-595. 被引量:40
  • 2陈中举,李丽,张蓓,简翠,王斌,田磊.2059株中段尿分离菌的分布及耐药性分析[J].中华医院感染学杂志,2009,19(2):225-227. 被引量:56
  • 3De Francesco MA, Ravizzola G, Peroni I., et al. Urinary tract in{ections in Brescia, Italy: etiology of uropathogens and antimicrobial resistance of common uropathogens[J]. Med Sci Monit, 2007, 13(6): BR136-144.
  • 4Karthikeyan K Kumarasamy, Mark A Toleman, Timothy R Walsh, et al. Emergence of a new antibiotic resistance mecha nism in India, Pakistan, and the UKt a molecular, biological, and epidemiological study[J] Lancet In{ect Dis, 2010. 10 (9) :597 602.

二级参考文献16

共引文献90

同被引文献74

  • 1Bader MS, Hawboldt J, Brooks A. Management of compli- cated urinary tract infections in the era of antimicrobial re- sistance[J]. Postgrad Med, 201 O, 122 ( 6 ) : 7.
  • 2Fluit AC, Jones ME, Schmitz F J, et al. Antimicrobial re- sistance among urinary tract infection (UTI) isolates in Europe: results from the SENTRY antimicrobial surveil- lance program 1997[J]. Antonie Van Leeuwenhoek, 2000, 77(2):147.
  • 3Turner KL, Moore L J, Todd SR, et al. Identification of cardiac dysfunction in sepsis with B-type natriuretic pep- tide[J]. JAm Coll Surg, 2011,213 ( 1 ) : 139.
  • 4Ruiz J, Pons M J, Gomes C. Transferable mechanisms of quinolone resistance[J]. Int J Antimicrob Agents, 2012, 10 (3):196.
  • 5Matthews DR, Hosker JP,Rudenski AS. Homeostasis model assessment :insulin resistance and beta-cell function from fast- ing plasma glucose and insulin eoncentrations in man[J]. Diabetologia, 1985, (07) : 412-419.
  • 6Dooko CBA, De Wit S, Neuhaus J, et al. Interleukin-6, High sensitivity c-reactive protein, and the development of type 2 diabetes among HIV-positive patients taking antiretro- viral therapy[J]. J Acquir Immune Defic Syndr, 2014, 67 (5) : 538-546.
  • 7Parving HH, Brenner BM, McMurray J/V, et al . Baseline characteristics in the aliskiren trial in type 2 diabetes using cardio-renal endpoints ( ALTITUDE ) [ J ]. J Renin Angiotensin Aldosterone Syst, 2012, 13 (3) : 387-393.
  • 8Dungan K, Binkley P, Osei K. GlycA is a novel marker of inflammation among non-critically ill hospitalized patients with type 2 diabetes[J]. Inflammation, 2015:1-7.
  • 9Shi L, Tan GS, Zhang K. Relationship of the serum CRP level with the efficacy of metformin in the treatment of type 2 diabetes mellitus: a meta-analysis [J]. J Clin Lab Anal, 2014. [Epub ahead of print].
  • 10Clinical and Laboratory Standards Institute.Performance standards for antimicrobial susceptibility testing:twenty second informational supplement[S].M100-S21.CLSI,2012.

引证文献9

二级引证文献68

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部